LLLorenz Latta

Lorenz Latta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lorenz Latta has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A stretchable human lung‐on‐chip model of alveolar inflammation for evaluating anti‐inflammatory drug response

    by Clémentine Richter, Lorenz Latta, Daria Harig, Patrick Carius, Janick D. Stucki, Nina Hobi, Andreas Hugi, Paul Schumacher, Tobias Krebs, Alexander Gamrekeli, et al.

    This study describes a complex human in vitro model for evaluating anti‐inflammatory drug response in the alveoli that may contribute to the reduction of animal testing in the pre‐clinical stage of drug development. The model is based on the human alveolar epithelial cell line Arlo co‐cultured with macrophages differentiated from the THP‐1 cell line, creating a physiological biological microenvironment. To mimic the three‐dimensional architecture and dynamic expansion and relaxation of the air‐blood‐barrier, they are grown on a stretchable microphysiological lung‐on‐chip. For validating the in vitro model, three different protocols have been developed to demonstrate the clinically established anti‐inflammatory effect of glucocorticoids to reduce certain inflammatory markers after different pro‐inflammatory stimuli: (1) an inflammation caused by bacterial LPS (lipopolysaccharides) to simulate an LPS‐induced acute lung injury measured best with cytokine IL‐6 release; (2) an inflammation caused by LPS at ALI (air‐liquid interface) to investigate aerosolized anti‐inflammatory treatment, measured with chemokine IL‐8 release; and (3) an inflammation with a combination of human inflammatory cytokines TNFα and IFNγ to simulate a critical cytokine storm leading to epithelial barrier disruption, where the eventual weakening or protection of the epithelial barrier can be measured. In all cases, the presence of macrophages appeared to be crucial to mediating inflammatory changes in the alveolar epithelium. LPS induction led to inflammatory changes independently of stretch conditions. Dynamic stretch, emulating breathing‐like mechanics, was essential for in vitro modeling of the clinically relevant outcome of epithelial barrier disruption upon TNFα/IFNγ‐induced inflammation.


  • Open Access

    Comparison of in vitro assays to study the effectiveness of antiparasitics against Acanthamoeba castellanii trophozoites and cysts

    by Lei Shi, Tanja Stachon, Lorenz Latta, Mohamed Ibrahem Elhawy, Erika Orosz, Albrecht F. Kiderlen, Berthold Seitz, Marukus Bischoff, Nóra Szentmáry

    Purpose: To compare LDH release assay, trypan blue and fluorescent stainings and non‐nutrient Escherichia coli (E. coli) plate assay in determining treatment efficacy of antiamoebic‐agents against Acanthamoeba castellanii trophozoites and cysts, in‐vitro.Methods: A. castellanii strain 1BU‐trophozoites/cysts were challenged with the antiamoebic‐agents 0.02% polyhexamethylen‐biguanid (PHMB), 0.1% propamidin‐isethionate (PD) and 0.0065% miltefosine (MF). Efficacies of the drugs were determined by LDH‐release and trypan blue assays. The fluorescent dyes Hoechst 33343, calcein‐AM, and ethidium‐homodimer‐1 were tested for their abilities to differentiate between viable and dead 1BU‐trophozoites/cysts following treatment, a non‐nutrient agar E. coli plate assay was applied to monitor the outgrowth of 1BU‐trophozoites/cysts challenged with antiamoebic‐agents.Results: All three antiamoebic‐agents induced a significant LDH‐release from trophozoites, when compared to controls (p < 0.0001). There was a negligible trypan blue, Hoechst33342, calcein‐AM and ethidium‐homodimer‐1 staining in untreated 1BU‐throphozoites and cysts. Percentage of trypan blue positive trophozoites/cysts was 59.3 ± 1.5% /100% after challenge with PHMB, 100%/99.3 ± 0.5% upon PD treatment, and 95.6 ± 2.5%/77.6 ± 5.1% when using MF. Hoechst 33342 stained 100%/100%, ethidium‐homodimer‐1 100%/100%, calcein‐AM 75.33 ± 4.04%/60.67 ± 3.51% of PHMB treated trophozoites/cysts. Hoechst 33342 and ethidium‐homodimer‐1 were 100%/100%, calcein‐AM 9.67 ± 2.52%/36.67 ± 4.51% positive in PD‐treated trophozoites/cysts. MF treatment resulted in 100%/100% Hoechst 33342 and ethidium‐homodimer‐1 positive trophozoites/cysts, while none of them became positive for calcein‐AM. On non‐nutrient agar E. coli plates, in controls and MF treated 1BU trophozoites/cysts, new trophozoites appeared within 24 hr, and encystment occured after 5 weeks of cultivation. In PHMB and PD treated 1BU‐throphozoites/cysts, irregularly shaped, smaller trophozoites appeared after 72 hr, which failed to form new cysts within 5 weeks.Conclusions: None of the enzymatic‐ and dye‐based viability assays tested here generated survival rates for trophozoites/cysts that were comparable with those yielded with the non‐nutrient agar E. coli plate assay, suggesting that the culture‐based assay is the best method to study the treatment efficacy of drugs against Acanthamoeba.

  • Open Access

    Comparison of in vitro assays to study the effectiveness of antiparasitics against Acanthamoeba castellani trophozoites and cysts

    by Lei Shi, Tanja Stachon, Lorenz Latta, Mohamed Ibrahem Elhawy, Gubesh Gunaratnam, Erika Orosz, Albrecht F. Kiderlen, Berthold Seitz, Markus Bischoff, Nóra Szentmáry

    We aimed to compare LDH release assay, trypan blue and fluorescent stainings, and non-nutrient Escherichia coli plate assay in determining treatment efficacy of antiamoebic agents against Acanthamoeba castellanii trophozoites/cysts, in vitro. 1BU trophozoites/cysts were challenged with 0.02% polyhexamethylene biguanid (PHMB), 0.1% propamidine isethionate (PD), and 0.0065% miltefosine (MF). Efficacies of the drugs were determined by LDH release and trypan blue assays, by Hoechst 33343, calcein-AM, and ethidium homodimer-1 fluorescent dyes, and by a non-nutrient agar E. coli plate assay. All three antiamoebic agents induced a significant LDH release from trophozoites, compared to controls (p < 0.0001). Fluorescent-dye staining in untreated 1BU trophozoites/cysts was negligible, but using antiamoebic agents, there was 59.3%–100% trypan blue, 100% Hoechst 33342, 0%–75.3% calcein-AM, and 100% ethidium homodimer-1 positivity. On E. coli plates, in controls and MF-treated 1BU trophozoites/cysts, new trophozoites appeared within 24 h, encystment occurred after 5 weeks. In PHMB- and PD-treated 1BU throphozoites/cysts, irregularly shaped, smaller trophozoites appeared after 72 h, which failed to form new cysts within 5 weeks. None of the enzymatic- and dye-based viability assays tested here generated survival rates for trophozoites/cysts that were comparable with those yielded with the non-nutrient agar E. coli plate assay, suggesting that the culture-based assay is the best method to study the treatment efficacy of drugs against Acanthamoeba.


  • Clinical anatomy of the anterior chamber angle in congenital aniridia and consequences for trabeculotomy/cyclophotocoagulation

    by Arne Viestenz, Berthold Seitz, Eva Deland, Miltiadis Fiorentzis, Lorenz Latta, Anja Viestenz, Barbara Käsmann‐Kellner

    Intraocular pressure lowering surgery in congenital aniridia glaucoma (CAG) can be complicated by dysgenesis of the limbal region, anterior chamber angle, iris, and lens. The anterior segments of 23 eyes (17 patients) with congenital aniridia were investigated under general anesthesia using ultrasound biomicroscopy (UBM). The structures of the anterior segment were examined: distance of ciliary body processes from the anterior chamber angle and positioning of Schlemm's canal. A surgical plan was created on the basis of these data. Schlemm's canal was detected in 21 of the 23 examined eyes. The mean distance from the anterior chamber angle was 1.3 ± 0.4 mm (range: 0.5–to 2.1 mm). The mean distance between the anterior chamber angle and the ciliary body was 561 ± 301 µm (range: 270–1,300 µm). The mean prominence of the ciliary body towards the lens was 799 ± 352 µm (range: 210–1,660 µm). This resulted in a precise UBM‐based trabeculotomy. In addition, the ciliary body was detected and coagulated ab externo with a diode laser probe (810 nm) using diaphanoscopy and UBM. An initial UBM examination of the anterior segment is essential in eyes with CAG scheduled for trabeculotomy or cyclophotocoagulation. Clin. Anat. 31:64–67, 2018.